High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer
- 7 February 2019
- book chapter
- Published by Springer Nature
- Vol. 1866, 149-161
Abstract
Methionine (MET) is a general target in cancer due to the excess requirement of MET by cancer cells. MET has been effectively restricted by recombinant methioninase (rMETase) in mouse models of cell-line tumors. This chapter reviews the efficacy of rMETase on patient-derived orthotopic xenograft (PDOX) mouse models of human cancer. Ewing’s sarcoma is a recalcitrant disease even though development of multimodal therapy has improved patients’ outcome. A Ewing’s sarcoma was implanted in the right chest wall of nude mice to establish a PDOX model. rMETase effectively reduced tumor growth compared to the untreated control. The MET level both of plasma and supernatants derived from sonicated tumors was lower in the rMETase treatment group. Body weight did not significantly differ at any time points between the two groups. A PDOX nude mouse model of a BRAF V600E-mutant melanoma was established in the chest wall of nude mice and also tested with rMETase in combination with a first-line melanoma drug, temozolomide (TEM). Combination therapy of TEM and rMETase was significantly more efficacious than either monotherapy. The results reviewed in this chapter demonstrate the clinical potential of rMETase.Keywords
This publication has 26 references indexed in Scilit:
- Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse modelOncotarget, 2017
- The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrenceOncotarget, 2017
- Is DNA methylation the new guardian of the genome?Molecular Cytogenetics, 2017
- The wayward methyl group and the cascade to cancerCell Cycle, 2017
- Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse modelOncotarget, 2016
- Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odysseyExpert Opinion on Biological Therapy, 2014
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Altered methionine metabolism occurs in all members of a set of diverse human tumor cell linesJournal of Cellular Physiology, 1984
- Reduced free‐methionine in methionine‐dependent SV40‐transformed human fibroblasts synthesizing apparently normal amounts of methionineJournal of Cellular Physiology, 1983
- Reduced availability of endogenously synthesized methionine for S-adenosylmethionine formation in methionine-dependent cancer cells.Proceedings of the National Academy of Sciences, 1982